Benitec Biopharma Inc.

1.54+0.3200+26.23%Vol 24.01M1Y Perf -70.39%
Jun 27th, 2022 16:00 DELAYED
BID1.50 ASK1.58
Open1.22 Previous Close1.22
Pre-Market- After-Market1.44
 - -  -0.10 -6.49%
Target Price
10.00 
Analyst Rating
Strong Buy 1.00
Potential %
549.35 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     46.68
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     43.77
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
19.80 
Earnings Rating
Strong Buy
Market Cap12.58M 
Earnings Date
18th May 2022
Alpha-0.05 Standard Deviation0.22
Beta1.60 

Today's Price Range

1.111.70

52W Range

0.74004.78

5 Year PE Ratio Range

-57.1083.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
83.27%
1 Month
52.46%
3 Months
-27.01%
6 Months
-44.00%
1 Year
-70.39%
3 Years
-86.29%
5 Years
-94.60%
10 Years
-

TickerPriceChg.Chg.%
BNTC1.540.320026.23
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
4.50
4.60
0.08
0.12
-815.40
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
98.70
-22 454.70
-21 880.00
-3 976.60
-
RevenueValueIndustryS&P 500US Markets
75.00K
0.01
-82.08
-39.68
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.44-0.409.09
Q02 2022--117.99-
Q01 2022--0.62-
Q04 2021--60.98-
Q03 2021--164.69-
Q02 2021--0.76-
----
----
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.2834.88Positive
6/2022 FY-1.899.13Positive
9/2022 QR-0.2935.56Positive
6/2023 FY-0.8735.07Positive
Next Report Date-
Estimated EPS Next Report-0.44
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume24.01M
Shares Outstanding8.17K
Shares Float154.12M
Trades Count60.77K
Dollar Volume34.35M
Avg. Volume9.99M
Avg. Weekly Volume23.87M
Avg. Monthly Volume4.56M
Avg. Quarterly Volume1.54M

Benitec Biopharma Inc. (NASDAQ: BNTC) stock closed at 1.54 per share at the end of the most recent trading day (a 26.23% change compared to the prior day closing price) with a volume of 24.01M shares and market capitalization of 12.58M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 14 people. Benitec Biopharma Inc. CEO is Jerel A. Banks.

The one-year performance of Benitec Biopharma Inc. stock is -70.39%, while year-to-date (YTD) performance is -41.22%. BNTC stock has a five-year performance of -94.6%. Its 52-week range is between 0.74 and 4.7799, which gives BNTC stock a 52-week price range ratio of 19.80%

Benitec Biopharma Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.98, a price-to-sale (PS) ratio of 98.06, a price to cashflow ratio of 2.80, a PEG ratio of 2.32, a ROA of -145.96%, a ROC of -175.13% and a ROE of -185.84%. The company’s profit margin is -%, its EBITDA margin is -21 880.00%, and its revenue ttm is $75.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Benitec Biopharma Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.44 for the next earnings report. Benitec Biopharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Benitec Biopharma Inc. is Strong Buy (1), with a target price of $10, which is +549.35% compared to the current price. The earnings rating for Benitec Biopharma Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Benitec Biopharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Benitec Biopharma Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.77, ATR14 : 0.17, CCI20 : 310.16, Chaikin Money Flow : -0.17, MACD : -0.08, Money Flow Index : 99.89, ROC : 25.10, RSI : 60.61, STOCH (14,3) : 41.38, STOCH RSI : 1.00, UO : 38.11, Williams %R : -58.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Benitec Biopharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Benitec Biopharma Inc.

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV).

CEO: Jerel A. Banks

Telephone: +1 510 780-0819

Address: 3940 Trust Way, Hayward 94545, CA, US

Number of employees: 14

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

47%53%

Bearish Bullish

59%41%

Bearish Bullish

55%45%

News

Stocktwits